Healthcare
Lupin Limited (lupin) Secures EMA Approval for Expanded Pediatric Indication for Namuscla®
Lupin Limited (LUPIN) secures EMA approval for expanded pediatric indication for NaMuscla®, broadening access to treatment for non-dystrophic myotonic disord.
Lupin Limited (Lupin) today announced that the European Medicines Agency (EMA) has approved a change to the terms of marketing authorization for NaMuscla, supported by the Pediatric Investigation Plan (PIP). This approval includes two new dosage strengths, 62 mg and 83 mg capsules, in addition to the existing 167 mg, and the revised indications that cover symptomatic treatment of myotonia in children (6–11 years, weighing at least 20 kg), adolescents (12–17 years), and adults (≥18 years) with non-dystrophic myotonic disorders.
Significance of the Approval
Claus Jepsen, President, Global Specialty, Lupin, stated, “This EMA approval for Pediatric Indication of NaMuscla represents a significant step forward for patients and families living with non-dystrophic myotonic disorders—especially children, where options are scarce. At Lupin, we remain committed to broadening access to therapies that improve outcomes across every stage of care.”
Expanded Access Across Europe
Lupin is now working towards making new dosage strengths and expanded pediatric indication available across Europe, subject to local implementation timelines and national reimbursement and access processes. This move is expected to provide more comprehensive treatment options for patients suffering from non-dystrophic myotonic disorders, particularly in pediatric populations where therapeutic options have been limited.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Lupin Limited
Lupin Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Lupin holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 0.16 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. The business compounds revenue at 19.1% and profits at 131.5% CAGR. That is strong double-digit growth on both counts. The stock trades at 89% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 19.1%, profits at 131.5%, and the PEG sits at 0.16 — below its growth rate. That combination is rare. Check Fundamentals of Lupin Limited.
Healthcare
Zydus Lifesciences Limited (zyduslife) Inspection by USFDA Concludes at Liqmeds, UK
Zydus Lifesciences Limited (ZYDUSLIFE) announces the closure of USFDA inspection at LiqMeds, UK with 4 observations.
Zydus Lifesciences Limited (ZYDUSLIFE) announced the closure of a USFDA inspection at LiqMeds, UK. The inspection took place from 9th to 13th November 2026 and concluded with four observations. The company will work closely with the USFDA to address these observations expeditiously.
Inspection Details
The USFDA conducted an inspection at LiqMeds, UK, focusing on compliance and operational standards. The four observations noted during the inspection will be addressed promptly to ensure full compliance with regulatory requirements.
Company’s Response
Zydus Lifesciences Limited is committed to maintaining high standards of quality and compliance. The company will collaborate closely with the USFDA to resolve the observations identified during the inspection. This proactive approach aims to expedite the resolution process and uphold the company’s reputation for quality and integrity.
As a result, Zydus Lifesciences Limited remains focused on its mission to deliver high-quality pharmaceutical products globally. The company’s dedication to addressing regulatory observations underscores its commitment to continuous improvement and adherence to international standards.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Zydus Lifesciences Limited
Zydus Lifesciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Zydus holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 0.67 signals undervaluation relative to growth. It is a potential re-rating candidate. The business compounds revenue at 16.5% and profits at 37.0% CAGR. That is strong double-digit growth on both counts. The stock trades at 70% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Revenue grows at 16.5% and profits at 37.0%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Zydus Lifesciences Limited.
ALKEM
Alkem Laboratories Limited Q2fy27: Revenue Growth of 14%
Alkem Laboratories Limited (ALKEM) reports 14% revenue growth in Q2FY27, with strong performance in both domestic and international segments.
Alkem Laboratories Limited (NSE: ALKEM) announced its standalone and consolidated financial results for the second quarter ended September 30, 2026, reflecting a robust performance. The Board of Directors reviewed these results at its meeting held in Mumbai today. Commenting on the results, Mr. Sandeep Singh, Managing Director of Alkem, stated, “Our Q2FY27 performance reflects continued momentum in the India business, supported by focused execution across our acute and chronic portfolios. The international business delivered steady progress despite continued pricing pressure in the US, with volume growth providing support.”
Q2FY27 Key Financial Highlights
Total Revenue from Operations was ₹45,520 million, with a year-on-year growth of 13.8%. India sales were ₹30,275 million, showing a YoY growth of 9.5%. International sales were ₹14,540 million, with a YoY growth of 22.3%. EBITDA at ₹10,252 million resulted in an EBITDA margin of 22.5%, a growth of 11.3% YoY. Profit before tax (before exceptional item) was ₹9,646 million, with a YoY growth of 7.7%. Net Profit (after Non-Controlling interest) was ₹6,753 million, with a YoY de-growth of 11.7%.
Operational Highlights
The contribution of domestic sales to total sales was 68% vs. 70% in Q2 FY26. US sales were ₹7,830 million, with a YoY growth of 2.4%. Non-US sales were ₹6,710 million, with a YoY growth of 58%.
For more information, please visit www.alkemlabs.com and follow us on LinkedIn, Instagram, and Facebook.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Alkem Laboratories Limited
Alkem Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Alkem moves sideways over three months, with neither buyers nor sellers taking control. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The PEG of 0.92 signals undervaluation relative to growth. It is a potential re-rating candidate. The stock gains 4.7% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 8.3% and profits at 32.7%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Alkem Laboratories Limited.
Healthcare
Suven Life Sciences Limited to Present Seven Scientific Posters at Neuroscience 2026
Suven Life Sciences Limited (SUVEN) to present seven scientific posters at Neuroscience 2026, showcasing CNS drug discovery.
Suven Life Sciences Limited (SUVEN) announced its participation in Neuroscience 2026, the annual meeting of the Society for Neuroscience (SfN), to be held in Washington, DC, USA, from November 14-18, 2026. The company will present seven scientific posters highlighting its drug discovery and development programs targeting central nervous system (CNS) disorders.
Diverse Portfolio of Drug Candidates
The presentations span a diverse range of therapeutic areas, including Alzheimer’s Disease, Agitation, Schizophrenia, Narcolepsy, Sleep Disorders, Major Depressive Disorder, and Parkinson’s Disease. The posters highlight Suven’s continued progress in advancing innovative drug candidates through clinical and preclinical development.
Key Presentations
Suven will present the following seven posters: SUVN-M8036: A Multimodal Receptor Antagonist That Exhibits Antipsychotic and Anti-Aggressive-Like Effects in Animal Models; SUVN-I6107 (Tenaclidine): Safety, Tolerability, and Pharmacokinetics of a Pure M1 Positive Allosteric Modulator: Results from a First-in-Human Study in Healthy Subjects; SUVN-L1101142: A Novel Muscarinic M4 Positive Allosteric Modulator for the Treatment of Alzheimer’s Disease and Schizophrenia; Samelisant: Efficacy and Safety of an H3 Receptor Inverse Agonist for the Treatment of Narcolepsy With or Without Cataplexy: A Phase 3 Study; SUVN-N9503012: Efficacy of a Selective 5-HT1A Receptor Partial Agonist Intended for the Treatment of L-Dopa-Induced Dyskinesia; Ropanicant (SUVN-911): A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety in Patients with Major Depressive Disorder; Masupirdine (SUVN-502): Baseline Characteristics from a Phase-3 Study in Alzheimer’s Dementia with Agitation.
Suven’s participation at Neuroscience 2026 reflects the breadth and continued progress of its CNS research and development pipeline. The company remains committed to advancing innovative therapies that address significant unmet medical needs, improve outcomes for patients, and create long-term value for the company.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Suven Life Sciences Limited
Suven Life Sciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Suven falls 14.9% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 5 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock holds at 55% of its 52-week range with RSI at 37. In other words, neither side has a clear edge right now. The stock holds up despite -19.3% revenue growth and a PEG of 99.00. That could signal an early turnaround. Alternatively, index flows simply support the price. Watch whether analysts revise estimates upward — that is the real signal. Check Fundamentals of Suven Life Sciences Limited.
-
Consumer Defensive3 days agoCupid Limited (NSE: Cupid) Q2 FY27: Net Profit Growth of 133% Yoy; H1 FY27 Net Profit Rises 156% Yoy to ₹100.37 Crore
-
ADANIENT3 days agoAdani Enterprises Limited (adanient) Kutch Copper First Indian Producer to Receive Veramark Assurance Certification
-
TATAPOWER3 days agoTata Power Delivers Highest-ever Quarterly Profit (tatapower) Q2 FY27: PAT Up 33% Yoy
-
Information Technology Services2 days agoLtm Limited (LTM) Introduces Ai-powered Quantum Error Mitigation to IBM Quantum Functions Catalog
-
ECLERX2 days agoEclerx Services Limited (eclerx) Announces Acquisition of Regedge
-
RATEGAIN2 days agoRategain Travel Technologies Limited (NSE: Rategain) Partners with Uzbekistan Airways to Enhance Pricing Agility
-
Consumer Cyclical3 days agoPopular Vehicles and Services Limited Q2 & H1 FY27: Revenue Up 57% Yoy, Service Growth Strong
-
AYE3 days agoAye Finance Limited (AYE) Receives ICRA Upgrade to A+ (stable Outlook)